Sinovac Life Sciences Co., Ltd.
Clinical trials sponsored by Sinovac Life Sciences Co., Ltd., explained in plain language.
A Chinese biopharmaceutical company focused on vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New 24-Valent vaccine aims to shield children from more pneumonia strains Results expected Sep 2026 (estimated)
- New meningitis vaccine enters first human tests Results expected Sep 2026 (estimated)
- New shot aims to block deadly tetanus after dirty wounds Results expected Mar 2027 (estimated) 🚀 Make-or-break
- New baby vaccine could fight pneumonia Results expected Jul 2027 (estimated) 🚀 Make-or-break
-
New vaccine aims to shield against 24 pneumonia strains
Vaccine CompletedThis study tested a new 24-valent pneumococcal conjugate vaccine (PCV24) in 385 healthy adults aged 18 and older. The goal was to check its safety and how well it triggers an immune response compared to an existing vaccine. Participants received one dose of either a low, middle, …
Phase 1/2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New rotavirus vaccine passes first safety check in early trial
Vaccine CompletedThis early-stage study tested a new oral rotavirus vaccine in 100 healthy people, from infants to adults. The main goal was to see if the vaccine is safe and well-tolerated. Researchers also checked how well the vaccine triggers an immune response in infants. The study was comple…
Phase 1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 11:03 UTC
-
New 24-Valent pneumonia vaccine shows promise in kids trial
Vaccine CompletedThis early-stage trial tested a new 24-valent pneumococcal conjugate vaccine in 119 healthy children aged 2 to 17. The goal was to see if the vaccine is safe and helps the body build immunity against pneumococcal bacteria, which can cause pneumonia and other serious infections. R…
Phase 1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
New pneumonia vaccine shows promise in early trial
Vaccine CompletedThis early-phase study tested a new 13-valent pneumococcal conjugate vaccine in 310 healthy volunteers ranging from 6-week-old infants to adults up to 49 years old. The goal was to check the vaccine's safety and how well it triggers the immune system to fight pneumococcal bacteri…
Phase 1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
New tetanus antibody could replace Blood-Derived treatments
Disease control CompletedThis completed Phase 1/2 trial tested a new lab-made antibody called SNA02-48 for treating tetanus in 255 Chinese adults. The study compared SNA02-48 to the standard treatment (human tetanus immunoglobulin) to see if it is safe and how well it works. The goal is to find a more re…
Phase 1/2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC